SCHEMBL13115656

SCHEMBL13115656

CCOC(=O)Cc1nc(-c2ccccc2)oc1-c1ccc(Cl)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.50
TRPM8 Q7Z2W7 1/20 0.46
KDM4E B2RXH2 3/20 0.45
HSD17B10 Q99714 3/20 0.44
TARBP2 Q15633 1/20 0.44
NPC1 O15118 1/20 0.43
PKM P14618 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 4/20 0.42
HPGD P15428 2/20 0.42
KMT2A Q03164 2/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13115652 0.91 HSD17B10 (0.54) SMN1; SMN2TRPM8KDM4EHSD17B10TARBP2
SCHEMBL2818845 0.89 HSD17B10 (0.45) SMN1; SMN2TRPM8KDM4EHSD17B10TARBP2
SCHEMBL13115699 0.89 HSD17B10 (0.44) SMN1; SMN2KDM4EHSD17B10TARBP2NPC1
SCHEMBL13116221 0.89 TARBP2 (0.48) KDM4EHSD17B10TARBP2NPC1PKM
SCHEMBL13116031 0.88 HSD17B10 (0.44) SMN1; SMN2KDM4EHSD17B10TARBP2NPC1
SCHEMBL13115697 0.88 HSD17B10 (0.46) SMN1; SMN2KDM4EHSD17B10TARBP2L3MBTL1
SCHEMBL13116080 0.87 HSD17B10 (0.45) SMN1; SMN2KDM4EHSD17B10TARBP2NPC1
SCHEMBL13116048 0.87 MEN1 (0.43) SMN1; SMN2KDM4EHSD17B10NPC1RAB9A
SCHEMBL13116035 0.86 TRPM8 (0.38) SMN1; SMN2TRPM8KDM4EHSD17B10NPC1
SCHEMBL13116081 0.86 HSD17B10 (0.39) SMN1; SMN2TRPM8KDM4EHSD17B10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256165-A1 LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER HONGU MITSUYA 2010-10-07 US disclosed
US-20100256165-A1 LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER HONGU MITSUYA 2010-10-07 US disclosed
US-7759373-B2 Large conductance calcium-activated K channel opener MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-20 US disclosed
US-7759373-B2 Large conductance calcium-activated K channel opener MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256165-A1 LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER KCNN3, KCNN2, KCNN1 SMN1; SMN2 2843/4885TRPM8 90/4885KDM4E 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.